Preliminary Results of a Phase 1 Study of the Safety and Tolerability of the Combination of Revumenib (REV) With Gilteritinib (GILT) in Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML)

Poster Presentation | Dec 6, 2025

Author

Borate U, et al.

Congress

American Society of Hematology Annual Meeting 2025

Orlando, Florida | Dec 6 – 9, 2025